Tag: drug class
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…
-
There Is A Warning About Increased Risk Of Lower Limb Amputations For Invokana And Invokamet (Only)
Going Into 2019 The Issue Of These Amputations Being An SGLT2 Inhibitors Drug Class Side Effect Remains Open To Debate (Posted by Tom Lamb at DrugInjuryWatch.com) A year-and-a-half ago we wrote this…
-
Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects It Now Appears, According To New Medical Evidence
Earlier Invokana Lower Limb Amputation Reports Are Being Followed By Farxiga And Jardiance Amputation Cases Now (Posted by Tom Lamb at DrugInjuryWatch.com) There is new medical evidence which suggests the hypovolemic effect…
-
New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With “joint pain that can be severe and disabling”
Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced…